Related Experiment Video
Updated: Jun 4, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Dyslipidemia and lipid management in HIV-infected patients
1Department of Medicine, Harvard Medical School, Program in Nutritional Metabolism, Massachusetts General Hospital, Boston, Massachusetts 02114, USA. jlo@partners.org
Insights
Dyslipidemia is common in people with chronic HIV infection. Rosuvastatin shows promise for managing high cholesterol in this group, but drug interactions must be considered.
Area of Science:
- Cardiology
- Infectious Diseases
- Pharmacology
Background:
- Dyslipidemia is prevalent in patients with chronic HIV infection.
- This condition may increase cardiovascular disease risk in this population.
Purpose of the Study:
- To review recent data on lipid abnormalities in HIV-infected patients.
- To summarize current management strategies for dyslipidemia in this cohort.
Main Methods:
- Literature review of studies published within the last year.
- Focus on novel lipid-lowering therapies evaluated in HIV patients.
Main Results:
- Several new lipid-lowering therapies have been assessed in HIV-infected individuals.
- Rosuvastatin demonstrates good tolerability and efficacy for hypercholesterolemia in this population.
Conclusions:
- Dyslipidemia remains a significant concern for individuals with HIV.
- Management requires careful consideration of potential drug-drug interactions between lipid-lowering agents and antiretroviral therapy.
Purpose Of Review:
Dyslipidemia is highly prevalent among patients living with chronic HIV infection and may confer increased risk of cardiovascular disease in this patient population. This review summarizes recent data investigating lipid abnormalities and its management in HIV-infected patients.
Recent Findings:
Studies in the last year have evaluated the effects of various lipid-lowering therapies not previously investigated in the HIV patient population. Rosuvastatin is a potent statin that appears to be well tolerated and effective in HIV-infected patients with hypercholesterolemia.
Summary:
Dyslipidemia is common in HIV-infected individuals. Medical therapy of lipid disorders needs to take potential drug-drug interactions of lipid-lowering medications and antiretroviral agents into consideration.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Angina IV: Management
Retrovirus Life Cycles
Sexually Transmitted Infections
Inhibitors of Viral Protein Synthesis
